Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology

Steeds, Richard P.; Stiles, Craig E; Sharma, Vishal; Chambers, John; Lloyd, Guy; Drake, William M

doi:10.1111/cen.13940

Cited by 24 publications

(31 citation statements)

References 39 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study had a much greater incidence of clinically significant tricuspid regurgitation (27/50 cabergoline cases vs 9/50 controls) than was observed in any of the other studies. It used a different echocardiographic method for grading the tricuspid regurgitation severity to other papers, relying on "the extent to which retrograde flow filled the atrium or ventricle" (11), a method which is known to be error prone (14). The blinding conditions for the echocardiographers was not stated.…”

Section: Current Literature Controversies and Meta-analysismentioning

confidence: 99%

“…Provided that no significant valve lesions have been observed during cabergoline treatment, no further surveillance is required after its cessation (14).…”

Section: Screening Guidelinesmentioning

confidence: 99%

“…Were the latter set of guidelines and scoring system to be adopted, establishing a pool of operators with experience in echocardiography of carcinoid/drug induced heart disease so that variability is minimised may be a useful strategy. Similarly, clinicians using echocardiogram images or reports to advise on continuation or cessation of cabergoline therapy should be aware that the degree of regurgitation itself should not necessarily be a deciding factor and that other morphological aspects (e.g valve thickness and restricted valve mobility) should be carefully evaluated (14). It is recommended that a decision to stop cabergoline treatment should be considered if there is a change of >2 points (Table 2) on serial imaging after review by an operator with experience of drug induced or carcinoid valvulopathy.…”

Section: Screening Guidelinesmentioning

confidence: 99%

“…Summary of case control studies from Steeds et al(14).All patients were treated for hyperprolactinaemia with cabergoline for a minimum of 6 months prior to echocardiography. Values rounded to nearest whole number, mean ± SD unless stated.…”

mentioning

confidence: 99%

“…Scoring system for patients receiving dopamine agonist therapy from Steeds et al(14) and adapted from Bhattacharyya et al(28).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia

Stiles

Steeds

Drake

2021

Annales d'Endocrinologie

View full text Add to dashboard Cite

Link to publication on Research at Birmingham portal General rightsUnless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.• Users may freely distribute the URL that is used to identify this publication.• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.• User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) • Users may not further distribute the material nor use it for the purposes of commercial gain.Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version. Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

Section: Current Literature Controversies and Meta-analysismentioning

confidence: 99%

“…Provided that no significant valve lesions have been observed during cabergoline treatment, no further surveillance is required after its cessation (14).…”

Section: Screening Guidelinesmentioning

confidence: 99%

Section: Screening Guidelinesmentioning

confidence: 99%

mentioning

confidence: 99%

“…Scoring system for patients receiving dopamine agonist therapy from Steeds et al(14) and adapted from Bhattacharyya et al(28).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia

Stiles

Steeds

Drake

2021

Annales d'Endocrinologie

View full text Add to dashboard Cite

show abstract

The patient with hyperprolactinemia

Ayuk

2021

Assisted Reproduction Techniques

View full text Add to dashboard Cite

11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy

et al. 2022

View full text Add to dashboard Cite

Purpose To assess the potential for 11C-methionine PET (Met-PET) coregistered with volumetric magnetic resonance imaging (Met-PET/MRCR) to inform clinical decision making in patients with poorly visualized or occult microprolactinomas and dopamine agonist intolerance or resistance. Patients and methods Thirteen patients with pituitary microprolactinomas, and who were intolerant (n = 11) or resistant (n = 2) to dopamine agonist therapy, were referred to our specialist pituitary centre for Met-PET/MRCR between 2016 and 2020. All patients had persistent hyperprolactinemia and were being considered for surgical intervention, but standard clinical MRI had shown either no visible adenoma or equivocal appearances. Results In all 13 patients Met-PET/MRCR demonstrated a single focus of avid tracer uptake. This was localized either to the right or left side of the sella in 12 subjects. In one patient, who had previously undergone surgery for a left-sided adenoma, recurrent tumor was unexpectedly identified in the left cavernous sinus. Five patients underwent endoscopic transsphenoidal selective adenomectomy, with subsequent complete remission of hyperprolactinaemia and normalization of other pituitary function; three patients are awaiting surgery. In the patient with inoperable cavernous sinus disease PET-guided stereotactic radiosurgery (SRS) was performed with subsequent near-normalization of serum prolactin. Two patients elected for a further trial of medical therapy, while two declined surgery or radiotherapy and chose to remain off medical treatment. Conclusions In patients with dopamine agonist intolerance or resistance, and indeterminate pituitary MRI, molecular (functional) imaging with Met-PET/MRCR can allow precise localization of a microprolactinoma to facilitate selective surgical adenomectomy or SRS.

show abstract

Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology

Cited by 24 publications

References 39 publications

Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia

Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia

The patient with hyperprolactinemia

11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy

Contact Info

Product

Resources

About